Aktis Oncology Inc（AKTS）の財務AKTSAktis Oncology Inc

Aktis Oncology Inc (AKTS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is RF Filters, accounting for 57.1% of total sales, equivalent to $3.34M. Another important revenue stream is Foundry Fabrication Services. Understanding this composition is critical for investors evaluating how AKTS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Aktis Oncology Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -853.99%, while the net margin is -713.48%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AKTS converts its operational activities into shareholder value.

In the context of the broader market, AKTS competes directly with industry leaders such as ABUS and CGEM. With a market capitalization of $874.89M, it holds a significant position in the sector. When comparing efficiency, AKTS's gross margin of 100.00% stands against ABUS's 100.00% and CGEM's N/A. Such benchmarking helps identify whether Aktis Oncology Inc is trading at a premium or discount relative to its financial performance.

Aktis Oncology has shown a gross margin of 100% across recent quarters, but it has also reported increasing net losses, with a net income of -24,144,000 USD in Q2 2026. The forward P/E ratio is currently 0, indicating that the company is not expected to generate profits in the near term, but its revenue is on an upward trend, reaching 3,384,000 USD in Q2 2026.